Imatinib Eg Stada

Imatinib, the active ingredient in Imatinib Eg Stada, is a tyrosine kinase inhibitor presented as an oral tablet for oral use. It is indicated for the treatment of chronic myeloid leukemia and gastrointestinal stromal tumor in adult patients.

GNH USA supplies Imatinib Eg Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution. Clients benefit from dedicated regulatory support and transparent pricing.

Imatinib is a tyrosine kinase inhibitor used in hematologic and solid tumor indications. - Chronic Myeloid Leukemia (CML): reduces disease progression and improves survival. - Gastrointestinal Stromal Tumor (GIST): inhibits tumor growth and prolongs progression‑free survival. - Philadelphia‑positive Acute Lymphoblastic Leukemia (Ph+ ALL): contributes to remission induction and maintenance therapy.

Imatinib may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Edema: swelling of hands, feet, or periorbital area. - Fatigue: generalized tiredness. - Diarrhea: loose stools.

Serious or Rare Side Effects: - Hepatotoxicity: elevated liver enzymes or liver injury. - Severe neutropenia: marked reduction in white blood cells. - Cardiac failure: signs of reduced heart function. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

When prescribing Imatinib, clinicians should consider several safety and handling precautions. - Monitor blood counts: regular CBC to detect cytopenias. - Assess liver function: periodic LFTs for hepatotoxicity. - Evaluate cardiac status: baseline and periodic ECG in patients with cardiac risk. - Use caution in renal impairment: dose adjustment may be required. - Avoid in patients with known hypersensitivity to imatinib or its excipients. - Store at ambient temperature: keep below 25 °C, in original container, protect from moisture.

Imatinib interacts with several medicines that can alter its effectiveness or increase toxicity.

Major Interactions (Avoid): - CYP3A4 strong inhibitors (e.g., ketoconazole, clarithromycin): may increase imatinib plasma levels. - CYP3A4 strong inducers (e.g., rifampicin, carbamazepine): may reduce imatinib exposure.

Moderate Interactions (Monitor Closely): - Proton pump inhibitors: may affect absorption, monitor therapeutic response. - Antacids containing aluminum or magnesium: separate dosing by at least 2 hours. - Warfarin: may enhance anticoagulant effect, monitor INR. - Live attenuated vaccines: potential reduced efficacy, assess risk.